Drug Profile


Alternative Names: P-144; Peptide 144

Latest Information Update: 09 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Digna Biotech; University of Navarra
  • Developer Avadel Pharmaceuticals; Digna Biotech; ISDIN; University of Navarra
  • Class Peptides
  • Mechanism of Action Apoptosis stimulants; Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Age-related macular degeneration; Corneal ulcer; Dry eyes; Systemic scleroderma

Highest Development Phases

  • Phase II Systemic scleroderma
  • Preclinical Age-related macular degeneration; Corneal ulcer; Dry eyes; Glioblastoma; Pulmonary fibrosis
  • Discontinued Actinic keratosis; Burns; Fibrosis; Keloids; Psoriasis; Skin cancer

Most Recent Events

  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
  • 12 Oct 2016 Phase II development in Systemic scleroderma is ongoing in Germany, Hungary, italy, Poland, Spain and United Kingdom
  • 16 Apr 2016 Preclinical pharmacodynamics data in Glioblastoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top